Geron (GERN) Long-Term Debt Issuances (2011 - 2021)
Geron's (GERN) quarterly Long-Term Debt Issuances came in at $14.9 million in Q4 2021, up 2252.46% year-on-year from $633167.9 in Q4 2020, and up 2252.46% quarter-over-quarter from -$692000.0 in Q4 2020.
Geron (GERN) Long-Term Debt Issuances (2011 - 2021) Analysis & Trends
Geron has disclosed Long-Term Debt Issuances across 3 years of filings, most recently posting $14.9 million for Q4 2021.
- Long-Term Debt Issuances for Q4 2021 came in at $14.9 million, up 2252.46% year-over-year; the trailing twelve-month figure through Dec 2021 was $16.3 million (changed N/A YoY), and the FY2024 annual result was $121.1 million, up 307.81% from the prior year.
- Long-Term Debt Issuances came in at $14.9 million for Q4 2021 at Geron, up from -$692000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $14.9 million in Q4 2021 to a low of -$692000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Geron | 729,618.77 | 729,618.77 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 14.90 Mn |
| Dec 31, 2021 | 14.90 Mn |
| Dec 31, 2020 | -692,000.00 |
| Dec 31, 2020 | -692,000.00 |
| Dec 31, 2011 | 2.14 Mn |
| Dec 31, 2011 | 2.14 Mn |